Comparative Pharmacology
Head-to-head clinical analysis: FOSCARNET SODIUM versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSCARNET SODIUM versus VITRAVENE PRESERVATIVE FREE.
FOSCARNET SODIUM vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Foscarnet is an organic analog of inorganic pyrophosphate that selectively inhibits the DNA polymerase activity of herpesviruses, including cytomegalovirus (CMV) and herpes simplex virus (HSV), at the pyrophosphate binding site without requiring activation by thymidine kinase. It also inhibits HIV reverse transcriptase.
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
Induction: 60 mg/kg IV every 8 hours for 14–21 days, followed by maintenance: 90–120 mg/kg IV once daily. Infuse at no more than 1 mg/kg/min via central or peripheral line.
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 48 hours (range 24-88 hours), reflecting prolonged intracellular retention; clinical context necessitates dose adjustment for renal impairment and monitoring of renal function.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Primarily excreted unchanged by the kidney via glomerular filtration and tubular secretion; >80% of dose recovered in urine within 24 hours; minimal biliary or fecal excretion (<5%).
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category A/B
Category C
Antiviral
Antiviral